Eczema drug dupilumab may rewire itch signals in skin
NCT ID NCT04823130
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at how dupilumab, an injectable eczema drug, changes nerve fibers in the skin of 54 adults with moderate-to-severe atopic dermatitis and chronic itching. Researchers took skin biopsies to measure nerve density and branching before and after treatment. The goal was to understand the biological reasons behind the drug's itch-relieving effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dupilumab (injection)
What this could lead to
If successful, this could help explain how dupilumab reduces itching in eczema by affecting skin nerves, potentially guiding better treatments.
What could go wrong
This is a small, exploratory Phase 4 study focused on understanding mechanisms, not proving a cure. Results may not lead to new treatments directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 2760001
Münster, 48149, Germany
-
Investigational Site Number 8400001
Miami, Florida, 33136, United States
-
Investigational Site Number 8400002
East Windsor, New Jersey, 08520, United States